What is the plasma half-life of oral Methenolone Acetate and why does it matter for dosing?

Oral Methenolone Acetate carries a plasma elimination half-life of approximately 2–3 hours, meaning blood concentrations drop to half within that window. This short duration makes single daily dosing insufficient for stable anabolism; practitioners split the total daily amount into two or three equally timed administrations to maintain a reasonably flat serum curve throughout waking hours.

How quickly does Hilma Biocare Primobolan 25mg reach peak concentration after ingestion?

Peak serum Methenolone is typically reached within 1–2 hours of oral ingestion as GI-tract esterases cleave the acetate group and first-pass hepatic metabolism delivers the free compound into systemic circulation. The fast onset makes timing relative to training sessions straightforward for athletes who want elevated circulating levels during the workout window.

How does the release profile of oral Methenolone Acetate compare to injectable Methenolone Enanthate?

Injectable Methenolone Enanthate sustains measurable plasma levels for seven to ten days from a single depot injection; oral Methenolone Acetate returns to near-baseline within six to eight hours. The oral acetate therefore produces sharper peak-and-trough oscillations but offers significantly faster wash-out kinetics and dosing controllability — a meaningful advantage when adjusting the protocol mid-cycle.

Does the Hilma Biocare 25mg tablet strength make split dosing easier compared to lower-strength Primobolan tablets?

Yes — 25 mg per tablet is the highest per-tablet concentration commonly available for oral Methenolone Acetate. A 75 mg/day three-dose protocol resolves to exactly one tablet per administration with no scoring required, whereas lower-strength 5 mg or 10 mg tablets demand a larger pill count per dose. Fewer tablets per administration simplifies adherence to the tight timing intervals the short half-life demands.

Can the 25mg tablets be split if a lower per-dose amount is needed, and does this affect potency accuracy?

Physically splitting tablets is possible, but HPLC-verified per-tablet content guarantees accuracy only at the whole-tablet level. Hilma Biocare's release testing confirms the 25 mg content for the intact tablet against a certified reference standard; once a tablet is split, dose accuracy depends on the uniformity of the break. For users requiring sub-25 mg increments, a dedicated lower-strength formulation preserves the assayed precision of each administration. (2) angle_used

HPLC Verified

Hilma Biocare

Primobolan 25mg/tab 50 Tabletten by Hilma Biocare

Name: Primobolan 25mg/tab 50 Tablets by Hilma Biocare
Brand: Hilma Biocare
SKU: ORA-META-HIL-002
Price: 76.00 EUR
Availability: InStock

Hilma Biocare Primobolan supplies Methenolone Acetate at 25 mg per tablet across a 50-tablet pack — an orally active anabolic compound whose 2–3 hour plasma half-life defines the split daily-dosing structure required for stable serum maintenance. The acetate ester is cleaved in the gastrointestinal tract and liver, delivering peak circulating Methenolone within approximately 1–2 hours of ingestion; consistent administration timing is consequently the central variable governing blood-level stability throughout the day. Per-tablet potency is instrument-confirmed: HPLC analysis against a certified Methenolone Acetate reference standard is embedded in Hilma Biocare's GMP-certified batch release record, so every tablet in the 50-count pack carries a verified — not calculated — content figure.

€76.00Free shipping on orders over €300

In stock

Ships within 48 h Lab-tested batch

Short acetate ester enables rapid dose adjustments mid-protocol without multi-day lag.
25 mg per tablet — highest unit strength for this compound — minimises daily pill count.
HPLC-verified potency provides an instrument-derived content figure, not a calculated estimate.
Fast wash-out pharmacokinetics support tighter pre-competition timing control.
Oral route removes the need for oil-based injection equipment or injection-site management.
1-methyl structural modification reduces hepatic deactivation rate compared to unmethylated oral analogues.
Hilma Biocare's GMP-certified compression process ensures weight-consistent tablets across the 50-tablet pack.

Phase	Daily Dose	Dosing Note
Introductory (Weeks 1–2)	50 mg/day (2 × 25 mg tablets)	Two administrations 8–10 h apart; establishes baseline tolerance while respecting the 2–3 h half-life by avoiding single-dose loading.
Maintenance (Weeks 3–8)	75–100 mg/day (3–4 × 25 mg tablets)	Three equal doses at morning, midday, and evening intervals flatten peak-to-trough swings dictated by the short acetate half-life; fourth tablet optional for advanced users.
Pre-Competition / Taper (Weeks 9–12)	50–75 mg/day	Reducing dose 2–3 weeks before a deadline exploits rapid oral acetate wash-out; circulating Methenolone reaches minimal levels within 48 h of last dose.

Key takeaways

Expect a 2–3 hour plasma half-life — plan split dosing accordingly.
Time each tablet within 1–2 hours before target peak windows.
Choose 25 mg/tab strength to eliminate fractional-tablet guesswork.
Anticipate faster wash-out than injectable Methenolone Enanthate.
Confirm per-tablet potency via HPLC batch data before each cycle.

Oral Methenolone Acetate: A Pharmacokinetic Portrait

Hilma Biocare Primobolan (Methenolone Acetate 25 mg/tab) is an oral anabolic steroid whose clinical identity is shaped above all by its unusually short systemic half-life — a pharmacokinetic feature that distinguishes it sharply from its injectable counterpart, Methenolone Enanthate. Where the enanthate ester sustains measurable plasma concentrations for seven to ten days from a single intramuscular depot, the acetate oral tablet delivers its active fraction in a compressed time window: published pharmacokinetic data place the plasma elimination half-life of oral Methenolone Acetate at approximately 2–3 hours, requiring true multiple-daily-dosing to replicate the flat serum curve a depot injection produces passively.

Absorption, Peak, and the Acetate Cleavage Event

Methenolone Acetate reaches peak serum concentrations roughly 1–2 hours after oral ingestion, as GI-tract esterases and first-pass hepatic metabolism cleave the acetate moiety and release free Methenolone into systemic circulation. The liver represents the rate-limiting step: first-pass extraction is non-trivial, which is why oral bioavailability for this compound is meaningfully lower than for 17-alpha-alkylated orals such as Oxandrolone. Despite this, the 1-methyl structural modification on Methenolone's A-ring substantially retards hepatic deactivation compared to unmethylated analogues, preserving a usable fraction of the dose. Compared to injectable Methenolone Enanthate, the oral acetate form produces a sharper, higher peak followed by a faster return toward baseline — a release profile that favours athletes who require dosing controllability and rapid wash-out over those seeking once-weekly convenience.

Dosing Frequency as the Primary Pharmacokinetic Control

Because the half-life dictates that circulating Methenolone falls to roughly 12–25 % of peak concentration within six hours, the dosing interval becomes the primary pharmacokinetic control variable. Practitioners commonly divide the daily target dose into two to three equal portions — morning, midday, and evening administrations — to blunt the peak-to-trough oscillation inherent to short-acting acetate esters. Hilma Biocare's 25 mg tablet strength accommodates this split-dosing framework with genuine numerical precision: a 75 mg/day protocol, for example, resolves into exactly three tablets without any need to score or estimate fractions. HPLC-verified per-tablet content, confirmed against a certified reference standard at Hilma Biocare's GMP-certified facility, ensures that each of the three daily administrations carries the assayed dose rather than a nominal one.

Usage

Establish your total daily dose target based on bodyweight, experience level, and cycle goals before opening the pack, using the pharmacokinetic rationale that the 2–3 h half-life requires division into at least two equal portions.
Set fixed daily administration times — for example 07:00, 13:00, and 19:00 — separated by 6–8 hours to align refill dosing with declining plasma concentrations from the previous tablet.
Swallow each 25 mg tablet whole with a full glass of water alongside a meal or moderate-fat snack; dietary fat marginally improves GI-tract absorption of lipophilic steroids.
Administer the pre-workout dose approximately 60–90 minutes before training so peak serum Methenolone — reached within 1–2 hours of ingestion — aligns with the anabolic stimulus of resistance exercise.
Log tablet consumption times in a training diary; because the half-life is short, a missed dose cannot be compensated by doubling the next tablet — simply resume the regular schedule at the next planned interval.
Complete the full planned cycle length before reassessing response; the fast wash-out profile means that any dose reductions or cycle terminations produce measurable serum clearance within 24–48 hours, offering genuine pharmacokinetic flexibility not available with longer-ester injectables.

Warnings

Contraindications: Not suitable for individuals with existing hepatic impairment, prostate pathology, or hypersensitivity to Methenolone or any related androgen. Contraindicated in women of childbearing potential due to virilisation risk. Persons under 21 years of age should not use anabolic steroids. Pre-existing cardiovascular conditions — including dyslipidaemia or hypertension — require physician clearance before use.

Side Effects: Oral Methenolone Acetate suppresses endogenous testosterone production via hypothalamic–pituitary–gonadal axis feedback, even at moderate doses. Androgenic effects including accelerated scalp hair thinning (in genetically predisposed individuals) and mild sebaceous activity increases are possible. Unlike 17-alpha-alkylated orals, hepatotoxicity risk is considerably lower, but LFT monitoring remains advisable for cycles exceeding eight weeks. Lipid-panel changes — particularly HDL suppression — have been documented at therapeutic doses.

Monitoring: Obtain baseline bloodwork covering LFTs (ALT, AST), full lipid panel, haematocrit, and serum testosterone prior to the cycle. Repeat the lipid panel and LFTs at the midpoint of any run lasting longer than eight weeks. Blood pressure should be self-monitored weekly given androgen-related fluid and cardiovascular effects.

PCT: Post-cycle therapy is required following any Methenolone Acetate protocol of meaningful duration. Because the oral acetate clears the bloodstream within 48 hours of the final tablet, PCT with a SERM (Clomiphene Citrate 50 mg/day or Tamoxifen Citrate 20 mg/day) can commence promptly — typically 48–72 hours after the last dose. PCT duration of four weeks is standard for cycles up to twelve weeks.

Frequently asked questions

What is the plasma half-life of oral Methenolone Acetate and why does it matter for dosing?: Oral Methenolone Acetate carries a plasma elimination half-life of approximately 2–3 hours, meaning blood concentrations drop to half within that window. This short duration makes single daily dosing insufficient for stable anabolism; practitioners split the total daily amount into two or three equally timed administrations to maintain a reasonably flat serum curve throughout waking hours.
How quickly does Hilma Biocare Primobolan 25mg reach peak concentration after ingestion?: Peak serum Methenolone is typically reached within 1–2 hours of oral ingestion as GI-tract esterases cleave the acetate group and first-pass hepatic metabolism delivers the free compound into systemic circulation. The fast onset makes timing relative to training sessions straightforward for athletes who want elevated circulating levels during the workout window.
How does the release profile of oral Methenolone Acetate compare to injectable Methenolone Enanthate?: Injectable Methenolone Enanthate sustains measurable plasma levels for seven to ten days from a single depot injection; oral Methenolone Acetate returns to near-baseline within six to eight hours. The oral acetate therefore produces sharper peak-and-trough oscillations but offers significantly faster wash-out kinetics and dosing controllability — a meaningful advantage when adjusting the protocol mid-cycle.
Does the Hilma Biocare 25mg tablet strength make split dosing easier compared to lower-strength Primobolan tablets?: Yes — 25 mg per tablet is the highest per-tablet concentration commonly available for oral Methenolone Acetate. A 75 mg/day three-dose protocol resolves to exactly one tablet per administration with no scoring required, whereas lower-strength 5 mg or 10 mg tablets demand a larger pill count per dose. Fewer tablets per administration simplifies adherence to the tight timing intervals the short half-life demands.
Can the 25mg tablets be split if a lower per-dose amount is needed, and does this affect potency accuracy?: Physically splitting tablets is possible, but HPLC-verified per-tablet content guarantees accuracy only at the whole-tablet level. Hilma Biocare's release testing confirms the 25 mg content for the intact tablet against a certified reference standard; once a tablet is split, dose accuracy depends on the uniformity of the break. For users requiring sub-25 mg increments, a dedicated lower-strength formulation preserves the assayed precision of each administration. (2) angle_used

Manufacturer

Hilma Biocare's release pathway for Methenolone Acetate 25mg/tab is structured around per-compound analytical checkpoints rather than a portfolio-wide blanket certificate: the incoming API consignment undergoes HPLC identity confirmation and quantitative potency measurement referenced against a certified Methenolone Acetate standard; the resulting dataset is locked into a batch-exclusive record assigned only to this SKU. From that intake data point, the production file tracks the material through GMP-certified tablet compression — where per-tablet weight uniformity is a controlled parameter — and terminates with a finished-product HPLC re-verification step that generates an instrument-produced per-tablet content figure. It is this instrument-derived value, not a theoretical fill calculation, that authorises the sealed 50-tablet pack for release. A LAL (Limulus Amebocyte Lysate) endotoxin test completes the release dossier for any oral solid-dosage batch leaving the facility.

Product details

Brand	Hilma Biocare
Active ingredient	methenolone acetate
Also known as	Primobolan Tablets, Methenolon Acetate, Primobolan, Hilma Biocare Primobolan Tablets
Strength	25 mg
Form	Tabletten
Pack size	50 pieces
Item number	ORA-META-HIL-002

Reviews

No reviews yet. Be the first to review this product.

Write a review

Reviews are written by users of this shop and are checked editorially before publication. Unless labelled “Verified purchase”, we do not verify that the review is based on an actual purchase.

Similar products

Primobolan Tablets 25mg/tab 50 Tablets by Genesis

Lab Tested

Primobolan Tablets 25mg/tab 50 Tabletten by Genesis

Genesis Primobolan Tablets deliver Methenolone Acetate at 25 mg per tablet — a DHT-lineage anabolic compound whose 5α-reduced, 1-methylated backbone drives selective androgen receptor (AR) agonism with a distinctly low androgenic side-effect profile relative to its anabolic output. Because the molecule is not recognised by aromatase (CYP19A1), AR-mediated gene transcription — rather than estrogenic conversion — is the sole driver of its pharmacological activity. Quality is locked in at source: every released batch passes HPLC potency verification against a certified Methenolone Acetate reference standard, with endotoxin burden evaluated by LAL assay under documented GMP conditions.

€80.00

Primoxyl 25mg/tab 50 Tablets by Kalpa Pharmaceuticals

Pharma Grade

Primoxyl 25mg/tab 50 Tabletten by Kalpa Pharmaceuticals

Primoxyl by Kalpa Pharmaceuticals delivers Methenolone Acetate at 25 mg per tablet across a 50-tablet pack — an oral anabolic compound formulated to provide controlled systemic Methenolone exposure despite the bioavailability ceiling imposed by first-pass hepatic metabolism on the oral route relative to injectable Methenolone Enanthate. The acetate ester enables meaningful intestinal absorption, yet clinical pharmacology data confirm that systemic availability via the oral pathway falls substantially short of the near-complete absorption achieved through intramuscular depot injection — a pharmacokinetic gap that directly shapes how practitioners construct and calibrate oral dosing protocols. Quality assurance at Kalpa Pharmaceuticals rests on three sequential checkpoints: raw API acceptance by HPLC potency assay, finished-tablet content uniformity testing, and a bacterial endotoxin screen using the LAL method — all conducted within a GMP-certified manufacturing environment.

€76.00

Primobolan Tabs 25mg/tab 50 Tablets by Magnus Pharmaceuticals

Batch Tested

Primobolan Tabs 25mg/tab 50 Tabletten by Magnus Pharmaceuticals

Magnus Pharmaceuticals Primobolan Tabs deliver Methenolone Acetate at 25 mg per tablet across a 50-tablet format, formulated as a discrete oral solid specifically studied in the context of androgen receptor tolerance development and cycle-length management. Because prolonged continuous exposure to any androgen agonist can progressively attenuate receptor responsiveness, structured cycle intervals are built into evidence-based protocols for this compound. Each production lot undergoes third-party batch testing alongside in-house HPLC potency verification; tablet uniformity and microbiological status are documented before any unit reaches distribution.

€95.00

Primobolan Tablets 25mg/tab 40 Tablets by Sterling Knight Pharmaceuticals

Top Seller

Primobolan Tablets 25mg/tab 40 Tabletten by Sterling Knight Pharmaceuticals

Sterling Knight Pharmaceuticals Primobolan Tablets deliver Methenolone Acetate at 25 mg per tablet — a precisely calibrated unit dose that places full titration control in the athlete's hands across every phase of a structured oral Methenolone programme. Evidence-informed frameworks consistently trend toward conservative daily ranges of 25–50 mg, a shift that positions the 25 mg tablet as the most operationally versatile starting unit currently available for calibrated oral Methenolone use. Quality assurance is embedded at the batch level: every production run is validated by HPLC potency analysis and LAL endotoxin testing under GMP-certified manufacturing conditions, with certificates of analysis issued per lot.

€96.00

Stack it with

Pairs well with these products.

High Concentration

Quant-Equipoise 300mg/ml 10ml Vial by Beligas Pharmaceuticals

Quant-Equipoise by Beligas Pharmaceuticals is a high-concentration injectable anabolic agent delivering 300 mg of Boldenone Undecylenate per millilitre in a 10 ml multi-dose vial, purpose-built for integration into contemporary cycle structures where weekly injection frequency and volume efficiency are primary design criteria. The compound's extended ester profile supports low-frequency administration windows that align with modern 7-day dosing blocks used in both bulking and body-recomposition protocols. Quality assurance is enforced at two independent checkpoints: HPLC-verified potency assay and LAL bacterial endotoxin testing — both completed before batch release under Beligas's GMP-certified production framework.

€47.00

Bolden-250 250mg/ml 10x1ml Ampoules by BM Pharmaceuticals

Long-Acting Formula

Bolden-250 250mg/ml 10x1ml Ampullen by BM Pharmaceuticals

Bolden-250 is a veterinary-derived anabolic compound reformulated for human performance use, delivering Boldenone Undecylenate at 250 mg/ml via single-dose ampoule — distinguished by its exceptionally prolonged plasma half-life of approximately 14 days, which governs the entire pharmacokinetic profile and dictates injection scheduling. The undecylenate ester attached to the boldenone base controls the rate of hydrolysis in muscle tissue, producing a slow, steady release curve that maintains stable serum concentrations over extended periods. Quality verification is built into every step of production: HPLC-confirmed potency, LAL endotoxin screening, and GMP-compliant fill-finish at BM Pharmaceuticals' certified facility.

€48.00

Brand Quality

EquiTrex 350mg/ml 10ml Vial by Concentrex Labs

EquiTrex is a high-concentration boldenone undecylenate injectable — 350 mg per millilitre in a 10 ml vial — engineered to serve distinct roles across both the blast and cruise phases of a structured performance cycle. Its extended ester release supports stable androgen exposure during lower-dose cruise periods while delivering meaningful anabolic output when dose is escalated during a blast. Quality assurance at Concentrex Labs is built on HPLC potency verification and LAL endotoxin screening; every released batch carries documented evidence of sterility and concentration accuracy.

€52.00

Pro Choice

EQ 300 300mg/ml 10ml Vial by Dragon-Pharma

Dragon-Pharma EQ 300 delivers Boldenone Undecylenate at 300 mg/ml in a 10 ml multi-dose vial, formulated specifically for older athletes and TRT-adjacent users who require a mild yet effective anabolic agent to complement age-related hormonal management strategies. Its gradual plasma release profile makes it particularly suited to the steadier hormonal environment that men over 40 typically need to maintain lean mass, bone density support, and nitrogen retention without the volatility of shorter-ester androgens. Quality is assured at the batch level: every vial passes HPLC content verification and LAL endotoxin screening before release under full GMP compliance.

€44.00